查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600679

隐球菌病市场：依治疗方法、通路分类 - 全球预测 2025-2030

Cryptococcosis Market by Treatment (Amphotericin B, Fluconazole, Flucytosine), Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年隐球菌病市场价值为59.1亿美元，预计到2024年将达到63.5亿美元，复合年增长率为7.64%，预计到2030年将达到99亿美元。

隐球菌病是严重的真菌感染疾病，主要影响免疫力的人群，特别是爱滋病毒/爱滋病患者，并在全世界构成重大健康挑战。免疫力缺乏低下个体数量的增加和对真菌感染疾病认识的提高强调需要有效的隐球菌病诊断和治疗解决方案。治疗应用整体医疗保健产业，重点在于诊断工具、抗真菌药物和免疫疗法。最终用途集中在医院、专科诊所和研究机构，其中准确的诊断和有效的治疗至关重要。市场成长受到诊断测试技术进步、医疗保健支出增加以及新型疗法的出现等因素的显着影响。潜在的商机在于扩大快速、准确诊断的范围，并提高抗真菌药物的有效性，以惠及发展中地区服务不足的人。鼓励公司投资行动诊所并与当地医疗保健提供者伙伴关係，以覆盖更多人并改善就诊机会。然而，挑战依然存在，例如资源匮乏环境下的意识低、治疗成本高、抗药性菌株的出现。新药认证的监管障碍也可能阻碍市场成长。在更有效的疫苗研究和对抗抗药性菌株的生物技术进步方面，创新机会比比皆是。探索基因组技术以更好地了解病原体抗药性机制并提供个人化治疗具有巨大潜力。最终，市场动态呈现出一个充满活力的格局，在全球卫生优先事项的更广泛背景下提供了巨大的成长机会。透过利用策略伙伴关係关係、专注于永续和创新的医疗保健解决方案以及解决经济和监管障碍，公司可以响应并利用隐球菌病市场不断变化的需求，并最终为改善公共卫生和扩大市场做出贡献。

主要市场统计
基准年[2023] 59.1亿美元
预测年份 [2024] 63.5亿美元
预测年份 [2030] 99亿美元
复合年增长率（%） 7.64%

市场动态：揭示快速发展的隐球菌病市场的关键市场洞察

供需的动态交互作用正在改变隐球菌病市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病和致命性真菌疾病的盛行率增加
    • 对爱滋病毒/爱滋病相关隐球菌病的深入了解
    • 学名药的供应量增加
  • 市场限制因素
    • 患者对治疗的临床认识有限
    • 由于感染隐球菌病的患者死亡率增加，检测和诊断范围缩小
  • 市场机会
    • 开发隐球菌脑膜炎有效治疗方法的政府优惠计划
    • 增加隐球菌病的药物开发和临床试验生态系统开发
  • 市场挑战
    • 与使用隐球菌病药物相关的副作用
    • 製药公司无法满足需求且药物开发专案资金不足

波特的五力：驾驭隐球菌病市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解隐球菌病市场的外部影响

外部宏观环境因素在塑造隐球菌病市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解隐球菌病市场的竞争状况

对隐球菌病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脚本 Coccosis 市场供应商的绩效评估

FPNV定位矩阵是评估隐球菌市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和致命真菌病的盛行率增加
      • 关于爱滋病毒/爱滋病相关隐球菌病的新发现
      • 提高学名药的供应
    • 抑制因素
      • 患者临床治疗意识的局限性
      • 由于感染患者死亡率增加，检测和诊断范围缩小
    • 机会
      • 政府首选计划开发隐球菌脑膜炎的有效治疗方法
      • 隐球菌病药物开发的增加和临床试验生态系统的演变
    • 任务
      • 与使用隐球菌病药物相关的副作用
      • 由于製药公司无法满足需求，药物开发计画资金不足
  • 市场区隔分析
    • 治疗：Amphotericin B主要用于治疗严重的隐球菌病病例。
    • 分销管道：零售药局是轻鬆快速取得隐球菌病药物的好选择。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 隐球菌病市场（依治疗）

  • 两性霉素B
  • Fluconazole
  • Flucytosine

第七章 隐球菌病市场：按分销管道

  • 医院药房
  • 通讯药房
  • 零售药局/药局

第八章美洲隐球菌病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区隐球菌病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的隐球菌病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Astellas来製药完成对 Propeller Therapeutics 的收购
    • 诺华透过收购 DTx Pharma 加强神经科学产品线和 xRNA 平台能力
    • 葛兰素史克同意收购后期生物製药公司 BELLUS Health

公司名单

  • Bausch Health Companies Inc.
  • Astellas Pharma Inc.
  • Citron Pharma
  • Novartis AG
  • Glenmark Pharmaceuticals Limited
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sigmapharm Laboratories, LLC
  • Skyepharma Production SAS
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • NuCare Pharmaceuticals, Inc.
  • Lunan Pharmaceutical Group
  • BM Pharmaceuticals
  • Merck & Co., Inc.
  • Matinas Biopharma Holdings, Inc.
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Jolly Limited
  • Abbott Laboratories
  • GlaxoSmithKline PLC
Product Code: MRR-4348D129F9A0

The Cryptococcosis Market was valued at USD 5.91 billion in 2023, expected to reach USD 6.35 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 9.90 billion by 2030.

Cryptococcosis, a serious fungal infection primarily affecting individuals with compromised immune systems, particularly those with HIV/AIDS, poses critical health challenges worldwide. The growing prevalence of immunocompromised individuals and increased awareness about fungal infections underscore the market necessity for effective diagnostic and therapeutic solutions against cryptococcosis. Applications span the healthcare industry, focusing on diagnostic tools, antifungal drugs, and immunotherapy treatments. End-use extends primarily to hospitals, specialty clinics, and research institutions where accurate diagnosis and efficient treatment are imperative. Market growth is significantly influenced by factors like technological advancements in diagnostic testing, increasing healthcare expenditure, and the rise of novel therapeutics. Potential opportunities lie in expanding access to rapid and accurate diagnostic methods and enhancing antifungal drug efficacy to reach underserved populations in developing regions. One recommendation is for companies to invest in mobile health clinics and partnerships with local healthcare providers to improve reach and accessibility. However, challenges persist, including limited awareness in low-resource settings, the high cost of treatment, and the development of drug-resistant strains. The regulatory hurdles in new drug approvals can also impede market growth. Innovation opportunities abound in research for more effective vaccines and biotechnological advancements to counteract resistant strains. There is substantial potential in exploring genomic technologies to understand the pathogen's resistance mechanisms better and tailoring individualized therapy. Ultimately, the cryptococcosis market presents a dynamic landscape with significant opportunities for growth, vested in the broader context of global health priorities. By leveraging strategic partnerships, focusing on sustainable and innovative healthcare solutions, and addressing economic and regulatory barriers, businesses can navigate and capitalize on the evolving demands of the cryptococcosis market, ultimately contributing to public health improvements and market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 5.91 billion
Estimated Year [2024] USD 6.35 billion
Forecast Year [2030] USD 9.90 billion
CAGR (%) 7.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cryptococcosis Market

The Cryptococcosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
    • Rising Insights into HIV/AIDS-Associated Cryptococcosis
    • Increasing Availability of Generic and Over-the-Counter Medicine
  • Market Restraints
    • Limited Clinical Awareness in Patients Regarding Treatments
    • Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
  • Market Opportunities
    • Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
    • Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
  • Market Challenges
    • Side Effects Associated with The Usage of Cryptococcosis Drugs
    • Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs

Porter's Five Forces: A Strategic Tool for Navigating the Cryptococcosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cryptococcosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cryptococcosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cryptococcosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cryptococcosis Market

A detailed market share analysis in the Cryptococcosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cryptococcosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cryptococcosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cryptococcosis Market, highlighting leading vendors and their innovative profiles. These include Bausch Health Companies Inc., Astellas Pharma Inc., Citron Pharma, Novartis AG, Glenmark Pharmaceuticals Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Bayer AG, Sigmapharm Laboratories, LLC, Skyepharma Production SAS, Pfizer Inc., Sumitomo Pharma Co., Ltd., Johnson & Johnson Services, Inc., NuCare Pharmaceuticals, Inc., Lunan Pharmaceutical Group, B.M. Pharmaceuticals, Merck & Co., Inc., Matinas Biopharma Holdings, Inc., Gilead Sciences, Inc., Sanofi S.A., Jolly Limited, Abbott Laboratories, and GlaxoSmithKline PLC.

Market Segmentation & Coverage

This research report categorizes the Cryptococcosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Amphotericin B, Fluconazole, and Flucytosine.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Mail Order Pharmacies, and Retail Pharmacies & Drug Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
      • 5.1.1.2. Rising Insights into HIV/AIDS-Associated Cryptococcosis
      • 5.1.1.3. Increasing Availability of Generic and Over-the-Counter Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Clinical Awareness in Patients Regarding Treatments
      • 5.1.2.2. Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
      • 5.1.3.2. Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects Associated with The Usage of Cryptococcosis Drugs
      • 5.1.4.2. Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
    • 5.2.2. Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Cryptococcosis Market, by Treatment

  • 6.1. Introduction
  • 6.2. Amphotericin B
  • 6.3. Fluconazole
  • 6.4. Flucytosine

7. Cryptococcosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Mail Order Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Cryptococcosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cryptococcosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cryptococcosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Astellas Completes Acquisition of Propella Therapeutics
    • 11.3.2. Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma
    • 11.3.3. GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company BELLUS Health

Companies Mentioned

  • 1. Bausch Health Companies Inc.
  • 2. Astellas Pharma Inc.
  • 3. Citron Pharma
  • 4. Novartis AG
  • 5. Glenmark Pharmaceuticals Limited
  • 6. Viatris Inc.
  • 7. Teva Pharmaceutical Industries Ltd.
  • 8. Bristol-Myers Squibb Company
  • 9. Eisai Co., Ltd.
  • 10. Takeda Pharmaceutical Company Limited
  • 11. Bayer AG
  • 12. Sigmapharm Laboratories, LLC
  • 13. Skyepharma Production SAS
  • 14. Pfizer Inc.
  • 15. Sumitomo Pharma Co., Ltd.
  • 16. Johnson & Johnson Services, Inc.
  • 17. NuCare Pharmaceuticals, Inc.
  • 18. Lunan Pharmaceutical Group
  • 19. B.M. Pharmaceuticals
  • 20. Merck & Co., Inc.
  • 21. Matinas Biopharma Holdings, Inc.
  • 22. Gilead Sciences, Inc.
  • 23. Sanofi S.A.
  • 24. Jolly Limited
  • 25. Abbott Laboratories
  • 26. GlaxoSmithKline PLC

LIST OF FIGURES

  • FIGURE 1. CRYPTOCOCCOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CRYPTOCOCCOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRYPTOCOCCOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023